Scientific article

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population

Published inLancet, vol. 362, no. 9387, p. 877-878
Publication date2003

Because of high death rates in the past, patients with HIV-1 cannot obtain life insurance. We measured mortality rates in the Swiss HIV Cohort Study (SHCS) from 1997 to 2001 and compared them with those of the Swiss reference population. In patients who were successfully treated with highly active anti-retroviral therapy (HAART), and who were not also infected with the hepatitis C virus, excess death rates were below five per thousand per year. Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies.

  • Adult
  • Antiretroviral Therapy, Highly Active
  • Cohort Studies
  • Comorbidity
  • Female
  • Follow-Up Studies
  • HIV Infections/drug therapy/epidemiology/ mortality
  • Hiv-1
  • Hepatitis C/epidemiology/mortality
  • Humans
  • Insurance, Life/statistics & numerical data
  • Male
  • Mortality
  • Switzerland/epidemiology
  • Treatment Outcome
Citation (ISO format)
JAGGY, Christian et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. In: Lancet, 2003, vol. 362, n° 9387, p. 877–878. doi: 10.1016/S0140-6736(03)14307-3
Updates (1)
ISSN of the journal0140-6736

Technical informations

Creation06/21/2010 10:24:56 AM
First validation06/21/2010 10:24:56 AM
Update time03/14/2023 3:44:16 PM
Status update03/14/2023 3:44:15 PM
Last indexation10/18/2023 9:24:44 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack